JP2016199549A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016199549A5 JP2016199549A5 JP2016095779A JP2016095779A JP2016199549A5 JP 2016199549 A5 JP2016199549 A5 JP 2016199549A5 JP 2016095779 A JP2016095779 A JP 2016095779A JP 2016095779 A JP2016095779 A JP 2016095779A JP 2016199549 A5 JP2016199549 A5 JP 2016199549A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- amino acid
- acid sequence
- individual
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100033625 Killer cell immunoglobulin-like receptor 2DS3 Human genes 0.000 claims description 133
- 108010077854 Natural Killer Cell Receptors Proteins 0.000 claims description 133
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 90
- 239000012634 fragment Substances 0.000 claims description 88
- 150000001875 compounds Chemical class 0.000 claims description 78
- 208000004346 Smoldering Multiple Myeloma Diseases 0.000 claims description 44
- 208000010721 smoldering plasma cell myeloma Diseases 0.000 claims description 44
- 208000014951 hematologic disease Diseases 0.000 claims description 33
- 230000003211 malignant effect Effects 0.000 claims description 33
- 208000019838 Blood disease Diseases 0.000 claims description 32
- 208000018706 hematopoietic system disease Diseases 0.000 claims description 32
- 210000004027 cell Anatomy 0.000 claims description 31
- 230000003902 lesion Effects 0.000 claims description 30
- 101001027081 Homo sapiens Killer cell immunoglobulin-like receptor 2DL1 Proteins 0.000 claims description 29
- 102100037363 Killer cell immunoglobulin-like receptor 2DL1 Human genes 0.000 claims description 29
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 27
- 230000002159 abnormal effect Effects 0.000 claims description 23
- 210000001185 bone marrow Anatomy 0.000 claims description 21
- 101710085938 Matrix protein Proteins 0.000 claims description 20
- 101710127721 Membrane protein Proteins 0.000 claims description 20
- 229920001184 polypeptide Polymers 0.000 claims description 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 18
- 201000009295 smoldering myeloma Diseases 0.000 claims description 18
- 101000945371 Homo sapiens Killer cell immunoglobulin-like receptor 2DL2 Proteins 0.000 claims description 17
- 102100033599 Killer cell immunoglobulin-like receptor 2DL2 Human genes 0.000 claims description 17
- 210000002966 serum Anatomy 0.000 claims description 17
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 16
- 210000004180 plasmocyte Anatomy 0.000 claims description 16
- 101000945333 Homo sapiens Killer cell immunoglobulin-like receptor 2DL3 Proteins 0.000 claims description 14
- 102100033634 Killer cell immunoglobulin-like receptor 2DL3 Human genes 0.000 claims description 14
- 210000000822 natural killer cell Anatomy 0.000 claims description 14
- 208000032839 leukemia Diseases 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 208000034578 Multiple myelomas Diseases 0.000 claims description 10
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 9
- 208000031404 Chromosome Aberrations Diseases 0.000 claims description 9
- 230000035772 mutation Effects 0.000 claims description 9
- 102000039446 nucleic acids Human genes 0.000 claims description 9
- 108020004707 nucleic acids Proteins 0.000 claims description 9
- 150000007523 nucleic acids Chemical class 0.000 claims description 9
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 8
- 238000001514 detection method Methods 0.000 claims description 8
- 239000002955 immunomodulating agent Substances 0.000 claims description 8
- 230000002584 immunomodulator Effects 0.000 claims description 8
- 229940121354 immunomodulator Drugs 0.000 claims description 8
- 230000002068 genetic effect Effects 0.000 claims description 7
- 230000008707 rearrangement Effects 0.000 claims description 7
- 108010043610 KIR Receptors Proteins 0.000 claims description 6
- 102000002698 KIR Receptors Human genes 0.000 claims description 6
- 239000002246 antineoplastic agent Substances 0.000 claims description 6
- 229940127089 cytotoxic agent Drugs 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 5
- 206010067477 Cytogenetic abnormality Diseases 0.000 claims description 5
- 206010060880 Monoclonal gammopathy Diseases 0.000 claims description 5
- 230000006378 damage Effects 0.000 claims description 5
- 239000003550 marker Substances 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108010069149 HLA-C*04 antigen Proteins 0.000 claims description 4
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims description 4
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims description 4
- 125000000539 amino acid group Chemical group 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 238000010494 dissociation reaction Methods 0.000 claims description 4
- 230000005593 dissociations Effects 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 230000004083 survival effect Effects 0.000 claims description 4
- 102100029382 CMRF35-like molecule 6 Human genes 0.000 claims description 3
- 101000990034 Homo sapiens CMRF35-like molecule 6 Proteins 0.000 claims description 3
- 101001109508 Homo sapiens NKG2-A/NKG2-B type II integral membrane protein Proteins 0.000 claims description 3
- 101000971513 Homo sapiens Natural killer cells antigen CD94 Proteins 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 claims description 3
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 claims description 3
- 108700042075 T-Cell Receptor Genes Proteins 0.000 claims description 3
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 3
- 239000013059 antihormonal agent Substances 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000012636 effector Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- 238000000684 flow cytometry Methods 0.000 claims description 3
- 230000013595 glycosylation Effects 0.000 claims description 3
- 238000006206 glycosylation reaction Methods 0.000 claims description 3
- 210000003714 granulocyte Anatomy 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 238000010837 poor prognosis Methods 0.000 claims description 3
- 230000017854 proteolysis Effects 0.000 claims description 3
- 238000001959 radiotherapy Methods 0.000 claims description 3
- 238000001356 surgical procedure Methods 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- 230000009885 systemic effect Effects 0.000 claims description 3
- 210000001519 tissue Anatomy 0.000 claims description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims 14
- 108091007433 antigens Proteins 0.000 claims 14
- 102000036639 antigens Human genes 0.000 claims 14
- 239000003112 inhibitor Substances 0.000 claims 8
- 230000005856 abnormality Effects 0.000 claims 2
- 230000000903 blocking effect Effects 0.000 claims 2
- 238000011443 conventional therapy Methods 0.000 claims 2
- 206010064571 Gene mutation Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 101150010487 are gene Proteins 0.000 claims 1
- 210000000349 chromosome Anatomy 0.000 claims 1
- 210000004324 lymphatic system Anatomy 0.000 claims 1
- 230000008816 organ damage Effects 0.000 claims 1
- 238000004393 prognosis Methods 0.000 claims 1
- 230000000392 somatic effect Effects 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 131
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 74
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 74
- 239000000203 mixture Substances 0.000 description 21
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41597310P | 2010-11-22 | 2010-11-22 | |
| US61/415,973 | 2010-11-22 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013541022A Division JP6224457B2 (ja) | 2010-11-22 | 2011-11-22 | Ｎｋ細胞調節治療及び悪性血液疾患の治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016199549A JP2016199549A (ja) | 2016-12-01 |
| JP2016199549A5 true JP2016199549A5 (enExample) | 2017-03-09 |
Family
ID=46146390
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013541022A Expired - Fee Related JP6224457B2 (ja) | 2010-11-22 | 2011-11-22 | Ｎｋ細胞調節治療及び悪性血液疾患の治療方法 |
| JP2016095779A Pending JP2016199549A (ja) | 2010-11-22 | 2016-05-12 | Ｎｋ細胞調節治療及び悪性血液疾患の治療方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013541022A Expired - Fee Related JP6224457B2 (ja) | 2010-11-22 | 2011-11-22 | Ｎｋ細胞調節治療及び悪性血液疾患の治療方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9844593B2 (enExample) |
| EP (1) | EP2643350A4 (enExample) |
| JP (2) | JP6224457B2 (enExample) |
| CN (2) | CN106963947A (enExample) |
| AR (1) | AR083957A1 (enExample) |
| BR (1) | BR112013012138B1 (enExample) |
| CA (1) | CA2818684C (enExample) |
| EA (1) | EA035033B1 (enExample) |
| MX (1) | MX355483B (enExample) |
| TW (1) | TWI664191B (enExample) |
| WO (1) | WO2012071411A2 (enExample) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090191213A9 (en) * | 2003-07-02 | 2009-07-30 | Novo Nordisk A/S | Compositions and methods for regulating NK cell activity |
| EP1835929B8 (en) * | 2005-01-06 | 2016-07-27 | Novo Nordisk A/S | Anti-kir combination treatments and methods |
| AU2012260601B2 (en) * | 2011-05-25 | 2018-02-01 | Innate Pharma, S.A. | Anti-KIR antibodies for the treatment of inflammatory disorders |
| US11471486B2 (en) | 2012-09-04 | 2022-10-18 | Inven2 As | Selective and controlled expansion of educated NK cells |
| SMT201700540T1 (it) | 2012-10-02 | 2018-01-11 | Bristol Myers Squibb Co | Combinazione di anticorpi anti-kir e di anticorpi anti-pd-1 per il trattamento del cancro |
| EA031025B1 (ru) | 2012-12-21 | 2018-11-30 | Сиэтл Дженетикс, Инк. | Антитела против ntb-a и связанные с ними композиции и способы |
| EP2948544A4 (en) | 2013-01-28 | 2016-08-03 | St Jude Childrens Res Hospital | CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR CELL THERAPY AGAINST CANCER AND INFECTION DISEASES |
| PT2992020T (pt) | 2013-05-03 | 2020-02-28 | Ohio State Innovation Foundation | Células efetoras imunes projetadas específicas do recetor de antígeno quimérico cs1 |
| EP3066128B1 (en) | 2013-11-06 | 2018-10-31 | Bristol-Myers Squibb Company | Combination of anti-kir and anti-cs1 antibodies to treat multiple myeloma |
| SG11201609118RA (en) | 2014-05-15 | 2016-11-29 | Univ Singapore | Modified natural killer cells and uses thereof |
| WO2015195555A1 (en) * | 2014-06-16 | 2015-12-23 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Blocking cd38 using anti-cd38 antibody conjugated to protein g to protect nk cells |
| US10617757B2 (en) | 2014-08-08 | 2020-04-14 | The Regents Of The University Of California | Methods for treating multiple myeloma |
| US10973914B2 (en) | 2015-02-20 | 2021-04-13 | Ohio State Innovation Foundation | Bivalent antibody directed against NKG2D and tumor associated antigens |
| RU2571551C1 (ru) * | 2015-04-16 | 2015-12-20 | Закрытое акционерное общество "ПЕПТЕК" | Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором |
| RS60753B1 (sr) | 2015-04-17 | 2020-10-30 | Bristol Myers Squibb Co | Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba |
| JP2018515138A (ja) | 2015-05-06 | 2018-06-14 | エスエヌアイピーアール・テクノロジーズ・リミテッドＳｎｉｐｒ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ | 微生物集団の改変および微生物相の修飾 |
| CA2986575A1 (en) | 2015-05-21 | 2016-11-24 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| EP3325967B1 (en) | 2015-07-24 | 2019-12-04 | Innate Pharma | Methods for detecting tissue infiltrating nk cells |
| AU2016349632A1 (en) | 2015-11-07 | 2018-05-24 | Multivir Inc. | Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| KR102369735B1 (ko) | 2016-05-20 | 2022-03-02 | 바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디. | 암을 치료하기 위한 면역요법과의 글루타메이트 조정제의 용도 |
| KR101926166B1 (ko) * | 2016-05-24 | 2018-12-06 | 재단법인 아산사회복지재단 | 수용체 시너지 활성을 이용한 nk 세포의 활성도 검사 방법 및 이를 이용한 nk 세포의 활성도가 관련된 질환의 진단 방법 |
| GB201609811D0 (en) | 2016-06-05 | 2016-07-20 | Snipr Technologies Ltd | Methods, cells, systems, arrays, RNA and kits |
| EP3518946A4 (en) | 2016-09-27 | 2020-09-09 | Board of Regents, The University of Texas System | METHODS TO IMPROVE IMMUNE CHECKPOINT BLOCKING TREATMENT BY MODULATING THE MICROBIOME |
| WO2018071668A1 (en) | 2016-10-12 | 2018-04-19 | Board Of Regents, The University Of Texas System | Methods and compositions for tusc2 immunotherapy |
| AU2017375958A1 (en) | 2016-12-12 | 2019-07-04 | Multivir Inc. | Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases |
| WO2018148223A1 (en) * | 2017-02-09 | 2018-08-16 | Memorial Sloan Kettering Cancer Center | Anti-kir3dl1 antibodies |
| CN110636851B (zh) | 2017-03-27 | 2023-11-03 | 新加坡国立大学 | 截短的nkg2d嵌合受体及其在自然杀伤细胞免疫疗法中的用途 |
| RU2019128544A (ru) | 2017-03-27 | 2021-04-28 | Нэшнл Юниверсити Оф Сингапур | Линии стимулирующих клеток для ex vivo размножения и активации клеток-натуральных киллеров |
| SG11201908396PA (en) | 2017-03-31 | 2019-10-30 | Bristol Myers Squibb Co | Methods of treating tumor |
| EP3621994A4 (en) | 2017-05-12 | 2020-12-30 | Harpoon Therapeutics, Inc. | MESOTHELIN BINDING PROTEINS |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| CN111630070B (zh) | 2017-10-13 | 2024-07-30 | 哈普恩治疗公司 | 三特异性蛋白质及使用方法 |
| US20200239577A1 (en) | 2017-10-15 | 2020-07-30 | Bristol-Myers Squibb Company | Methods of treating tumor |
| CA3089170A1 (en) | 2018-02-09 | 2019-08-15 | National University Of Singapore | Activating chimeric receptors and uses thereof in natural killer cell immunotherapy |
| EP3768698B1 (en) | 2018-03-19 | 2025-02-12 | MultiVir Inc. | Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer |
| KR102761890B1 (ko) | 2018-03-23 | 2025-02-06 | 브리스톨-마이어스 스큅 컴퍼니 | Mica 및/또는 micb에 대한 항체 및 그의 용도 |
| US10760075B2 (en) | 2018-04-30 | 2020-09-01 | Snipr Biome Aps | Treating and preventing microbial infections |
| KR20210006344A (ko) | 2018-03-25 | 2021-01-18 | 에스엔아이피알 바이옴 에이피에스. | 미생물 감염의 치료 및 예방 |
| CN111971306A (zh) | 2018-03-30 | 2020-11-20 | 百时美施贵宝公司 | 治疗肿瘤的方法 |
| SG11202008976YA (en) | 2018-04-02 | 2020-10-29 | Nat Univ Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| WO2019195769A1 (en) * | 2018-04-06 | 2019-10-10 | The Brigham And Women's Hospital, Inc. | Methods of diagnosing and treating aggressive cutaneous t-cell lymphomas |
| CN108728527B (zh) * | 2018-06-06 | 2020-06-09 | 青岛泱深生物医药有限公司 | Hcst基因作为诊治子痫前期的靶标 |
| US20210251994A1 (en) | 2018-06-15 | 2021-08-19 | Flagship Pioneering Innovations V, Inc. | Increasing immune activity through modulation of postcellular signaling factors |
| EP3844186A4 (en) | 2018-08-29 | 2022-08-17 | National University of Singapore | METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS |
| WO2020061482A1 (en) | 2018-09-21 | 2020-03-26 | Harpoon Therapeutics, Inc. | Egfr binding proteins and methods of use |
| EP3856771A4 (en) | 2018-09-25 | 2022-06-29 | Harpoon Therapeutics, Inc. | Dll3 binding proteins and methods of use |
| US20220054524A1 (en) | 2018-12-21 | 2022-02-24 | Onxeo | New conjugated nucleic acid molecules and their uses |
| KR102210455B1 (ko) * | 2019-02-28 | 2021-02-02 | 사회복지법인 삼성생명공익재단 | 자연살해세포 활성 검출용 미세입자 및 이를 이용한 검출 방법 |
| SG11202109057XA (en) | 2019-03-05 | 2021-09-29 | Nkarta Inc | Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| EP3962493A2 (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor |
| CN111973739B (zh) * | 2019-05-23 | 2024-02-13 | 正大天晴药业集团股份有限公司 | 抗pd-l1单克隆抗体治疗癌症的用途 |
| CN114174538A (zh) | 2019-05-30 | 2022-03-11 | 百时美施贵宝公司 | 适合于免疫肿瘤学疗法的多肿瘤基因特征 |
| WO2020243568A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy |
| WO2020243570A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Cell localization signature and combination therapy |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
| US20230114107A1 (en) | 2019-12-17 | 2023-04-13 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| TW202214857A (zh) | 2020-06-19 | 2022-04-16 | 法商昂席歐公司 | 新型結合核酸分子及其用途 |
| CN116096906A (zh) | 2020-06-29 | 2023-05-09 | 旗舰创业创新五公司 | 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途 |
| EP4178611A1 (en) | 2020-07-07 | 2023-05-17 | BioNTech SE | Therapeutic rna for hpv-positive cancer |
| CN114222761B (zh) * | 2020-07-14 | 2024-02-20 | 浙江道尔生物科技有限公司 | 一种抗cld18a2的单域抗体 |
| CN116438199A (zh) | 2020-08-31 | 2023-07-14 | 百时美施贵宝公司 | 细胞定位特征和免疫疗法 |
| JP2023549559A (ja) * | 2020-11-18 | 2023-11-27 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ナチュラルキラー細胞に対する枯渇モノクローナル抗体 |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| CA3201348A1 (en) | 2020-12-28 | 2022-07-07 | Masano HUANG | Antibody compositions and methods of use thereof |
| AU2021416156A1 (en) | 2020-12-28 | 2023-06-22 | Bristol-Myers Squibb Company | Methods of treating tumors |
| MX2023009100A (es) | 2021-02-03 | 2023-09-25 | Mozart Therapeutics Inc | Agentes aglutinantes y métodos para usar los mismos. |
| EP4314068A1 (en) | 2021-04-02 | 2024-02-07 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
| EP4370552A1 (en) | 2021-07-13 | 2024-05-22 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
| CA3227172A1 (en) * | 2021-07-28 | 2023-02-02 | Cai WU | Methods for treating acute myeloid leukemia with anti-ilt3 antibodies |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
| KR20240133795A (ko) | 2021-12-16 | 2024-09-04 | 발레리오 테라퓨틱스 | 신규한 컨쥬게이티드 핵산 분자 및 이의 용도 |
| KR20240159621A (ko) | 2022-03-18 | 2024-11-05 | 브리스톨-마이어스 스큅 컴퍼니 | 폴리펩티드를 단리하는 방법 |
| IL317319A (en) | 2022-06-02 | 2025-01-01 | Bristol Myers Squibb Co | Antibody compounds and methods of using them |
| GB202209518D0 (en) | 2022-06-29 | 2022-08-10 | Snipr Biome Aps | Treating & preventing E coli infections |
| IL321098A (en) | 2022-12-14 | 2025-07-01 | Astellas Pharma Europe Bv | Combination therapy including bispecific binding agents that bind to CLDN18.2- and CD3- and immune checkpoint inhibitors |
| WO2025038763A1 (en) | 2023-08-15 | 2025-02-20 | Bristol-Myers Squibb Company | Ceramic hydroxyapatite chromatography flow through method |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025121445A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030105294A1 (en) * | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| NZ536908A (en) * | 2002-05-17 | 2008-09-26 | Celgene Corp | Treating or preventing cancer comprising administering an effective amount of cytokine inhibitory drug plus a second active ingredient |
| SI1639013T1 (sl) * | 2003-07-02 | 2013-01-31 | Innate Pharma | Pan-kir2dl nk-receptorska protitelesca in njihova uporaba pri diagnosticiranju in terapiji |
| PL1639013T3 (pl) | 2003-07-02 | 2013-02-28 | Innate Pharma | Przeciwciała pan-kir2dl receptorów NK i ich zastosowanie w diagnostyce i leczeniu |
| BRPI0412890B8 (pt) * | 2003-07-24 | 2021-05-25 | Innate Pharma | método de selecionar um anticorpo anti kir2dl1 ou fragmento de anticorpo de ligação de antígeno |
| JP5112863B2 (ja) | 2004-07-01 | 2013-01-09 | ノヴォ ノルディスク アー／エス | ヒト抗−ｋｉｒ抗体 |
| EP1835929B8 (en) * | 2005-01-06 | 2016-07-27 | Novo Nordisk A/S | Anti-kir combination treatments and methods |
| ATE531733T1 (de) * | 2005-01-06 | 2011-11-15 | Novo Nordisk As | Kir-bindende wirkstoffe und verfahren zu ihrer verwendung |
| WO2008084106A1 (en) * | 2007-01-11 | 2008-07-17 | Novo Nordisk A/S | Anti-kir antibodies, formulations, and uses thereof |
| US20100099084A1 (en) | 2008-10-17 | 2010-04-22 | Maher Albitar | Detection of npm1 nucleic acid in acellular body fluids |
-
2011
- 2011-11-22 AR ARP110104349A patent/AR083957A1/es unknown
- 2011-11-22 EP EP11843281.4A patent/EP2643350A4/en not_active Ceased
- 2011-11-22 EA EA201390756A patent/EA035033B1/ru not_active IP Right Cessation
- 2011-11-22 WO PCT/US2011/061840 patent/WO2012071411A2/en not_active Ceased
- 2011-11-22 CN CN201710194545.4A patent/CN106963947A/zh active Pending
- 2011-11-22 JP JP2013541022A patent/JP6224457B2/ja not_active Expired - Fee Related
- 2011-11-22 MX MX2013005673A patent/MX355483B/es active IP Right Grant
- 2011-11-22 BR BR112013012138-6A patent/BR112013012138B1/pt not_active IP Right Cessation
- 2011-11-22 TW TW100142827A patent/TWI664191B/zh active
- 2011-11-22 CA CA2818684A patent/CA2818684C/en active Active
- 2011-11-22 US US13/988,954 patent/US9844593B2/en active Active
- 2011-11-22 CN CN2011800622682A patent/CN103298831A/zh active Pending
-
2016
- 2016-05-12 JP JP2016095779A patent/JP2016199549A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016199549A5 (enExample) | ||
| JP2014501729A5 (enExample) | ||
| US20220332816A1 (en) | Anti-tigit antibodies | |
| US8758749B2 (en) | Biological materials and uses thereof | |
| EP3621694B1 (en) | Lrrc33 inhibitors and use thereof | |
| US10611839B2 (en) | Anti CD84 antibodies, compositions comprising same and uses thereof | |
| KR20230131464A (ko) | 항-cd19 병용 요법 | |
| BR112013032217B1 (pt) | uso de um anticorpo anti-nkg2a | |
| KR20190038919A (ko) | 항-nkg2d 항체로 크론병을 치료하는 방법 | |
| US20230348611A1 (en) | Obinutuzumab treatment of a dlbcl patient subgroup | |
| TW202133877A (zh) | 全身性紅斑狼瘡中之ｉ型干擾素抑制 | |
| US11136383B2 (en) | Methods and compositions for modulaton of transforming growth factor beta-regulated functions | |
| US12116415B2 (en) | Anti-BCMA antibodies | |
| AU2020296124A1 (en) | Anti-TIM-3 antibodies | |
| Moszczuk et al. | The Role of Glomerular and Serum Expression of Lymphocyte Activating Factors BAFF and APRIL in Patient with Membranous and IgA Nephropathies | |
| JP2023523450A (ja) | 非小細胞肺がん免疫療法のための方法及び組成物 | |
| US20250320294A1 (en) | Bispecific antibody for t-cell modulation | |
| CA3048198A1 (en) | Methods of treating multiple myeloma | |
| HK40103766A (en) | Lrrc33 inhibitors and use thereof | |
| WO2025085512A9 (en) | Combination therapies with ulbp2 targeting antibodies for treating cancers | |
| CN117355330A (zh) | 抗cd19组合疗法 | |
| Vidal Crespo | Targeting the crosstalk between tumor cells and microenvironment: a new therapeutic approach for the treatment of lymphoid neoplasms |